.png)
Patient Access for All
Life Sciences
Case Background
A leading independent biopharmaceutical company successfully launched an innovative product targeting Dry-eye Disease (DED). To ensure early patient access, our Client introduced a Pharmacist Savings Offer at launch, allowing commercial patients awaiting coverage determination to obtain the medication at a substantially reduced cost. The company aimed to transition seamlessly from the current Savings Offer to a comprehensive Patient Support Program (PSP). This PSP would incorporate innovative elements designed to enhance patient experience, adherence, and outcomes, while also strategically expanding the company's market footprint. The company's proactive approach underscored its commitment to not only providing immediate financial relief but also fostering long-term patient support and market growth.
Photo by David Travis on Unsplash
We applied our innovation framework to develop breakthrough PSP solutions in close collaboration with the client team. The process began with the Discovery phase, where we conducted a comprehensive review of all available client materials, ensuring we had a deep understanding of their current PSP framework and market positioning. This was complemented by rapid primary research, including surveys and interviews with key stakeholders such as healthcare providers, patients, and payers. In the Design phase, our focus was on leveraging the insights from a precedent search across the therapeutic space and beyond the healthcare industry. We explored best practices and innovative approaches from various sectors, selecting the most relevant and impactful cases for our Creative Recombination workshop. This workshop, a core component of our methodology, facilitated collaborative brainstorming sessions where the client team and our experts generated multiple breakthrough ideas. As a final step, we provided extensive support to the client team in the execution phase. This included creating tailor-made communication materials designed to effectively convey the new PSP solutions to both internal and external stakeholders. We also developed a comprehensive business case for the leadership team, detailing the anticipated benefits, implementation roadmap, and key performance indicators to measure success.
Our Approach
23 full and partial ideas captured during the workshop were translated into 17 distinct PSP elements. Three immediate solutions with positive immediate TRx impact potential were refined and further develop with a high level of detail to support subsequent implementation efforts. As a result, multiple strategic PSP opportunities considered by the client team were distilled into four leading options, structured based on their respective TRx and revenue impact, and presented to the senior leadership. This enabled streamlined decision-making in the situation of major time constraints and helped mitigate serious operational risks.
Output
Patient Access for All
Life Sciences
Case Background
A leading independent biopharmaceutical company successfully launched an innovative product targeting Dry-eye Disease (DED). To ensure early patient access, our Client introduced a Pharmacist Savings Offer at launch, allowing commercial patients awaiting coverage determination to obtain the medication at a substantially reduced cost. The company aimed to transition seamlessly from the current Savings Offer to a comprehensive Patient Support Program (PSP). This PSP would incorporate innovative elements designed to enhance patient experience, adherence, and outcomes, while also strategically expanding the company's market footprint. The company's proactive approach underscored its commitment to not only providing immediate financial relief but also fostering long-term patient support and market growth.
Photo by David Travis on Unsplash
We applied our innovation framework to develop breakthrough PSP solutions in close collaboration with the client team. The process began with the Discovery phase, where we conducted a comprehensive review of all available client materials, ensuring we had a deep understanding of their current PSP framework and market positioning. This was complemented by rapid primary research, including surveys and interviews with key stakeholders such as healthcare providers, patients, and payers. In the Design phase, our focus was on leveraging the insights from a precedent search across the therapeutic space and beyond the healthcare industry. We explored best practices and innovative approaches from various sectors, selecting the most relevant and impactful cases for our Creative Recombination workshop. This workshop, a core component of our methodology, facilitated collaborative brainstorming sessions where the client team and our experts generated multiple breakthrough ideas. As a final step, we provided extensive support to the client team in the execution phase. This included creating tailor-made communication materials designed to effectively convey the new PSP solutions to both internal and external stakeholders. We also developed a comprehensive business case for the leadership team, detailing the anticipated benefits, implementation roadmap, and key performance indicators to measure success.
Our Approach
23 full and partial ideas captured during the workshop were translated into 17 distinct PSP elements. Three immediate solutions with positive immediate TRx impact potential were refined and further develop with a high level of detail to support subsequent implementation efforts. As a result, multiple strategic PSP opportunities considered by the client team were distilled into four leading options, structured based on their respective TRx and revenue impact, and presented to the senior leadership. This enabled streamlined decision-making in the situation of major time constraints and helped mitigate serious operational risks.